-
mission
Extending
Healthy Life Expectancy
Through ScienceSenotyx is taking on the inevitability
of aging through science, striving to create a world
where everyone can live in good health
until the final chapter of life. -
Vision
“Healthy Until 100”
Creating a society where everyone can aim to be
“Healthy Until 100”.
Senotyx
Value
Integrity in Science
A commitment to facing facts and continuously seeking the truth.
Patient-Centered Thinking
Placing the future patient’s quality of life above all else.
Challenge and Innovation
Breaking conventional boundaries to unlock new possibilities.
Ethics and Responsibility
A sense of duty as stewards of public healthcare.
Co-Creation and Growth
Creating new value through collaboration with diverse wisdom.
Science
Redefining the
future of medicine
by targeting senescent cells.
Senotyx is pioneering the next generation
of age-related disease therapy.
-
Next-generation senolytics (SenoVac):
immune-based, selective,
and
clinically translatable.Conventional senolytic treatments
have raised concerns due to
off-target effects on healthy cells.
In contrast, our innovative approach
selectively eliminates only pathogenic senescent cells.
-
30 years of cutting-edge
aging biology
– now driving
next-generation senolytics.Through our research, we have demonstrated
that the accumulation of senescent cells contributes
to age-related diseases such as atherosclerosis,
heart failure, and diabetes.
Suppressing these cells improves aging phenotypes.
Founder & CEO
CEO
Tohru Minamino
MD PhD
Professor, Juntendo University Graduate School of Medicine
Biography and Awards
-
1989
Graduated from Chiba University, School of Medicine
-
1997
Doctor of Medicine (University of Tokyo)
-
1997−2000
Harvard Medical School, Research Fellow
-
2001−2009
Assistant Professor, Department of Cardiovascular Science and Medicine, Graduate School of Medicine, Chiba University
-
2002
Japanese College of Cardiology YIA Excellence Award
-
2002
The Society of Cardiovascular Endocrinology and Metabolism YIA
-
2003
Okamoto Research Encouragement Award
-
2007
The Society of Cardiovascular Endocrinology and Metabolism Takamine Jokichi Research Encouragement Award
-
2010−2012
Associate professor, Department of Cardiovascular Science and Medicine, Graduate School of Medicine, Chiba University
-
2010
Japanese Circulation Society Sato Award
-
2010
Bertz Award (1st prize)
-
2011
Japan Medical Association Research Encouragement Award
-
2012−2020
Professor, Department of Cardiovascular Biology and Medicine, Graduate School of Medical and Dental Sciences, Niigata University
-
2019−2020
Deputy Director of Niigata University Medical & Dental Hospital (concurrent post)
-
2020-
Professor, Department of Cardiovascular Biology and Medicine, Graduate School of Medicine, Juntendo University
-
2025
Jokichi Takamine Award
Changing the Norms
Healthcare, Welfare,
Work, and Life Itself.
We are committed to daily research and practice
to create a society
where lifelong health is no longer exceptional.
Company
| Business name | Senotyx |
|---|---|
| Address | 2F, Ginza Otake Residence, 1-22-11 Ginza, Chuo-ku, Tokyo 104-0061, Japan |
| CEO | Tohru Minamino MD PhD |
| Business Description | Senotyx is taking on the inevitability of aging through science, striving to create a world where everyone can live in good health until the final chapter of life. |
Contact
Thank you for visiting the Senotyx website.
Fields marked with “*” are required.
Please make sure to fill them out and click the “Confirm Input” button.